Early stage biopharmaceutical company Lumos Pharma has raised $14 million in Series A financing led by Sante Ventures and New Enterprise Associates. The company will use the financing to support the preclinical and clinical development of its lead compound, LUM-001. LUM-001, which has been granted orphan designation by the FDA, is a small molecule therapeutic for the rare disease Creatine Transporter Deficiency, an inborn error of metabolism. Lumos Pharma intends to immediately initiate its development with the goal of receiving marketing authorization from regulatory bodies worldwide. As part of the transaction, Sante Ventures' Kevin Lalande and NEA's Ed Mathers will join the company's Board.